Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance

Chemico-Biological Interactions

Volumn 160, Issue 3, 2006, Pages 217-224

  Dzamitika, Simplice A ^a   Falcão, Camila A B ^b   De Oliveira, Fernanda B ^c   Marbeuf, Carole ^a   Garnier Suillerot, Arlette ^a   Demicheli, Cynthia ^d   Rossi Bergmann, Bartira ^b   Frézard, Frédéric ^c,d  

^a UNIVERSITÉ PARIS 13   (France)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Departamento de Microbiologia   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Antimony; Leishmania; Mechanism of action; Meglumine antimoniate; Metal resistance; MRP

Indexed keywords

ANTIMONY; MEGLUMINE ANTIMONATE; MULTIDRUG RESISTANCE PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; MOUSE; NONHUMAN;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CATIONS; CELL LINE; DRUG RESISTANCE, MICROBIAL; LEISHMANIA; LEISHMANIASIS; MEGLUMINE; MICE; MICE, INBRED BALB C; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOMETALLIC COMPOUNDS;

ANIMALIA; LEISHMANIA AMAZONENSIS; MAMMALIA;

EID: 33645401739     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2006.01.008     Document Type: Article

References (29)

1. J.D. Berman Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years Clin. Infect. Dis. 24 1997 684 703
2. C. Demicheli, and F. Frezard Pentavalent antimonials: from chemistry to the design of new drugs Drug Des. Rev. - Online 2 2005 243 249
3. T. Yi, M.K. Pathak, D.J. Lindner, M.E. Ketterer, C. Farver, and E.C. Borden Anticancer activity of sodium stibogluconate in synergy with IFNs J. Immunol. 169 2002 5978 5985
4. T. Gebel Arsenic and antimony: comparative approach on mechanistic toxicology Chem. Biol. Interact. 107 1997 131 144
5. C.S. Ferreira, P.S. Martins, C. Demicheli, C. Brochu, M. Ouellette, and F. Frézard Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione BioMetals 16 2003 441 446
6. C. Demicheli, F. Frézard, M. Lecouvey, and A. Garnier-Suillerot Antimony(V) complex formation with adenine nucleosides in aqueous solution Biochim. Biophys. Acta 1570 2002 192 198
7. C. Demicheli, N. Bouchemal, C.S. Ferreira, L.S. Santos, M.N. Eberlin, E. Hantz, and F. Frézard Synthesis and characterization of Sb(V)-adenosine and Sb(V)-guanosine complexes in aqueous solution Inorg. Chim. Acta 359 2006 159 167
8. J.L. Burguera, M. Burguera, Y. Petit de Pena, A. Lugo, and N. Anez Selective determination of antimony(III) and antimony(V) in serum and urine and of total antimony in skin biopsies of patients with cutaneous leishmaniasis treated with meglumine antimoniate Trace Elem. Med. 10 1993 66 70
9. Y. Zhou, N. Messier, M. Ouellette, B.P. Rosen, and R. Mukhopadhyay Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam J. Biol. Chem. 279 2004 37445 37451
10. M.A. Franco, A.C. Barbosa, S. Rath, and J.G. Dorea Antimony oxidation states in antileishmanial drugs Am. J. Trop. Med. Hyg. 52 1995 435 437
11. S. Rath, W.F. Jardim, and J.G. Dórea A simple spectrophotometric procedure for the determination of antimony(III) and (V) in antileishmanial drugs Fresenius J. Anal. Chem. 358 1997 548 550
12. D. Sereno, M. Cavaleyra, K. Zemzoumi, S. Maquaire, A. Ouaissi, and J.L. Lemesre Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action Antimicrob. Agents Chemother. 42 1998 3097 3102
13. S. Sundar, D.K. More, M.K. Singh, V.P. Singh, S. Sharma, P. Makharia, X. Kumar, and H.W. Murray Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian Epidemic Clin. Infect. Dis. 31 2000 1104 1107
14. M. Ouellette, J. Drummelsmith, and B. Papadopoulou Leishmaniasis: drugs in the clinic, resistance and new developments Drug Resist. Updat. 7 2004 257 266
15. S.P. Cole, G. Bhardwaj, J.H. Gerlach, J.E. Mackie, C.E. Grant, K.C. Almquist, A.J. Stewart, E.U. Kurz, A.M. Duncan, and R.G. Deeley Overexpression of a transporter gene in a multidrug-resistant human cancer cell line Science 258 1992 1650 1654
16. P. Borst, R. Evers, M. Kool, and J. Wijnholds A family of drug transporters: the multidrug resistance-associated proteins J. Natl. Cancer Inst. 92 2000 1295 1302
17. K.C. Ferreira-Pinto, A.L. Miranda-Vilela, C. Anacleto, A.P.S.M. Fernandes, M.C.B. Abdo, M.L. Petrillo-Peixoto, and E.S.A. Moreira Leishmania (V.) guyanensis: isolation and characterization of glucantime-resistant cell lines Can. J. Microbiol. 42 1996 944 949
18. C. Brochu, J. Wang, G. Roy, N. Messier, X.-Y. Wang, N.G. Saravia, and M. Ouellette Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony resistant parasites Antimicrob. Agents Chemother. 47 2003 3073 3079
19. L. Vernhet, A. Courtois, N. Allain, L. Payen, J.P. Anger, A. Guillouzo, and O. Fardel Overexpression of the multidrug resistance-associated protein (MRP1) in human heavy metal-selected tumor cells FEBS Lett. 443 1999 321 325
20. T. Katsura, and K. Inui Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation Drug Metab. Pharmacokin. 18 2003 1 15
21. C. Demicheli, R. Ochoa, J.B.B. da Silva, A.L. de Melo, C.A.M. Falcão, B. Rossi-Bergmann, R.D. Sinisterra, and F. Frézard Oral Delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis Antimicrob. Agents Chemother. 48 2004 100 103
22. C. Demicheli, R. Ochoa, I.S. Lula, F.C. Gozzo, M. Eberlin, and F. Frézard Pentavalent organoantimonial derivatives: two simple and efficient synthethic methods for meglumine antimonate Applied Organomet. Chem. 17 2003 226 231
23. F. Frézard, D. Demicheli, C.S. Ferreira, and M.A.P. Costa Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate Antimicrob. Agents Chemother. 45 2001 913 916
24. E.C. Torres-Santos, D. Moreira, M.A. Kaplan, and B. Rossi-Bergmann Selective effect of 2′-6′-dihydroxy-4′-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis Antimicrob. Agents Chemother. 43 1999 1234 1241
25. J.G. Zijlstra, E.G.E. De Vries, and N.H. Mulder Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line Cancer Res. 47 1987 1780 1784
26. W.L. Roberts, W.J. McMurray, and P.M. Rainey Characterization of the antimonial antileishmanial agent meglumine antimonate (glucantime) Antimicrob. Agents Chemother. 42 1998 1076 1082
27. W.L. Roberts, J.D. Berman, and P.M. Rainey In vitro antileishmanial properties of tri- and pentavalent antimonial preparations Antimicrob. Agents Chemother. 39 1995 1234 1239
28. T.J. Patterson, M. Ngo, P.A. Aronov, T.V. Reznikova, P.G. Green, and R.H. Rice Biological activity of inorganic arsenic and antimony reflects oxidation state in cultured human keratinocytes Chem. Res. Toxicol. 16 2003 1624 1631
29. S. Sundar, P.R. Sinha, N.K. Agrawal, N.K. Agrawal, R. Srivastava, P.M. Rainey, J.D. Berman, H.W. Murray, and V.P. Singh A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate Am. J. Trop Med Hyg. 59 1998 139 143